J.P. Morgan Asset Management: Life Sciences Innovation Summit


J.P Morgan Life Sciences Private Capital, Blue Horizon Advisors, and and United AlSaqer Group are sponsoring the inaugural J.P. Morgan Asset Management: Life Sciences Innovation Summit at the Cleveland Clinic Abu Dhabi on May 14 – 15th, 2024. The inaugural event seeks to attract top caliber, early stage entrepreneurs in life sciences to seed the growth of the emerging scientific innovation hub in Abu Dhabi. The two-day Summit will take place in conjunction with the Abu Dhabi Global Healthcare Week.

The Summit aims to bring together the life sciences leaders of today and the leaders of tomorrow who are building a wide range of innovative therapeutic solutions, including drugs, diagnostics, medical devices, and digital solutions, addressing diseases prevalent in the Emirati region.

J.P. Morgan Life Sciences Private Capital and Blue Horizon Advisors have invited 11 emerging companies to pitch to an industry-renowned judging panel. All finalists will have the potential opportunity to gain support from J.P. Morgan Life Sciences Private Capital, Blue Horizon Advisors, and other prominent regional investors to fuel their growth.


November 16, 2023
Applications Open
January 22, 2024
Submission Deadline
April 4, 2024
Finalist Announcement
May 14-15, 2024
Innovation Challenge
May 17, 2024
Winner Announcement

The Winner

Rayees Rahman, PhD

Dr. Rayees Rahman, PhD, is a co-founder and CEO of Harmonic Discovery. Dr. Rahman completed his PhD at the Icahn School of Medicine at Mount Sinai where he developed machine learning approaches to characterize the 3D structure of protein kinases and their inhibitors.


Honorable Mention

Chun-Hao Huang, PhD

Dr. Chun-Hao Huang is Co-Founder and CEO of Algen. Dr. Huang is a genetic engineer, drug developer and AI entrepreneur. He received his postdoctoral training at UC Berkeley under the mentorship of Nobel Laureate Professor Jennifer Doudna, and his PhD at Memorial Sloan-Kettering Cancer Center/Weill Cornell Medicine under HHMI Professors Scott Lowe and Charles Sherr. Dr. Huang pioneered genetically engineered models using advanced CRISPR and RNAi, which led to the discovery of new therapeutic strategies for treating cancer and inflammatory diseases. He also invented methods to identify disease biomarkers that predict drug responses and applied machine learning to the study of genes. Dr. Huang is the recipient of the UN’s Sustainable Development Goals Talent award of the 1st UNLEASH Global Innovation Lab, a Fellow of the 64th Lindau Nobel Laureate Meeting, and an AACR Basic Cancer Research Fellow. He has authored over 10 patents filed or issued, 40 scientific papers, and 3,000 citations across fields of biotechnology, AI, medicine in top-tier journals including Cell, Science, Nature Biotechnology, and Proceedings of the National Academy of Sciences (PNAS).




Laurie Glimcher, MD

President and CEO at Dana-Farber Cancer Institute

Jorge A. Guzman, MD

CEO at Cleveland Clinic Abu Dhabi

Shahrukh Khurshid Hashmi, MD

Director of Research at the Department of Health, Abu Dhabi

David Hung, MD

President and CEO at Nuvation Bio

Yasmine Kobeissi, PhD

Executive Director at Blue Horizon Advisors

Anya Schiess

Managing Partner at J.P. Morgan Life Sciences Private Capital


  • Onsite visits to innovation centers in Abu Dhabi
  • 1:1 meetings between finalists, J.P. Morgan Life Sciences Private Capital, Blue Horizon Advisors, and the judges
  • Welcome dinner
  • Pitch presentations
  • Keynote presentations by leading scientists and business leaders
  • Closing / award ceremony


  • Companies seeking funding for innovative therapeutics (including drugs, diagnostics, medical devices, and digital solutions)
  • Any stage of therapeutic development
  • Open domicile: submissions from all countries welcome
  • Private, registered, for-profit companies (LLC, C-Corp, S-Corp, etc.)

See terms and conditions here.


Applications will be judged by the following criteria:

Unmet Need

  • Strategic basis for addressing unmet needs of the patient population in the Emirati region
  • Target diseases include, but are not limited, to diabetes, obesity, cardiometabolic disease, oncology, sickle cell anemia, cystic fibrosis, lysosomal storage disease, and rare monogenic disorders


  • Potential of the innovation to improve patient outcomes

Market Feasibility

  • Differentiation strategy
  • Preliminary clinical development and regulatory strategy
  • Feasibility of development and implementation


  • Novelty of the technology
  • Relevant peer-reviewed scientific publications
  • Ability to protect the technology (i.e. IP)


  • Scalability
  • Organization expansion plans


As previewed, after a 10-week application period and a thorough analysis by expert scientists and investors, 11 applicants have been shortlisted as finalists and received an invitation to pitch their ideas and therapeutic solutions over the course of a two-day summit in Abu Dhabi on May 14th–15th, 2024.

An expert panel of judges, as further described below, will assess the innovators.

The challenge was accepting applications through January 22, 2024.

This website is a general communication being provided for informational purposes only. It is educational in nature and not designed to be a recommendation for any specific investment product, strategy, plan feature or other purposes. By receiving this communication you agree with the intended purpose described above. Any examples used in this material are generic, hypothetical and for illustration purposes only. None of J.P. Morgan Asset Management, its affiliates or representatives is suggesting that the recipient or any other person take a specific course of action or any action at all. Communications such as this are not impartial and are provided in connection with the advertising and marketing of products and services. Prior to making any investment or financial decisions, an investor should seek individualized advice from personal financial, legal, tax and other professionals that take into account all of the particular facts and circumstances of an investor’s own situation.

Opinions and statements of financial market trends that are based on current market conditions constitute our judgment and are subject to change without notice. We believe the information provided here is reliable but should not be assumed to be accurate or complete. The views and strategies described may not be suitable for all investors.

INFORMATION REGARDING INVESTMENT ADVISORY SERVICES:   J.P. Morgan Asset Management is the brand for the asset management business of JPMorgan Chase & Co. and its affiliates worldwide. Investment Advisory Services  provided by J.P. Morgan Investment Management Inc.

INFORMATION REGARDING MUTUAL FUNDS/ETF: Investors should carefully consider the investment objectives and risks as well as charges and expenses of a mutual fund or ETF before investing. The summary and full prospectuses contain this and other information about the mutual fund or ETF and should be read carefully before investing. To obtain a prospectus for Mutual Funds: Contact JPMorgan Distribution Services, Inc. at 1-800-480-4111 or download it from this site. Exchange Traded Funds: Call 1-844-4JPM-ETF or download it from this site.

J.P. Morgan Funds and J.P. Morgan ETFs are distributed by JPMorgan Distribution Services, Inc., which is an affiliate of JPMorgan Chase & Co. Affiliates of JPMorgan Chase & Co. receive fees for providing various services to the funds. JPMorgan Distribution Services, Inc. is a member of FINRA  FINRA’s BrokerCheck

INFORMATION REGARDING COMMINGLED FUNDS: For additional information regarding the Commingled Pension Trust Funds of JPMorgan Chase Bank, N.A., please contact your J.P. Morgan Asset Management representative.

The Commingled Pension Trust Funds of JPMorgan Chase Bank N.A. are collective trust funds established and maintained by JPMorgan Chase Bank, N.A. under a declaration of trust. The funds are not required to file a prospectus or registration statement with the SEC, and accordingly, neither is available. The funds are available only to certain qualified retirement plans and governmental plans and is not offered to the general public. Units of the funds are not bank deposits and are not insured or guaranteed by any bank, government entity, the FDIC or any other type of deposit insurance. You should carefully consider the investment objectives, risk, charges, and expenses of the fund before investing.

INFORMATION FOR ALL SITE USERS: J.P. Morgan Asset Management is the brand name for the asset management business of JPMorgan Chase & Co. and its affiliates worldwide.


Telephone calls and electronic communications may be monitored and/or recorded.

Personal data will be collected, stored and processed by J.P. Morgan Asset Management in accordance with our privacy policies at https://www.jpmorgan.com/privacy.

If you are a person with a disability and need additional support in viewing the material, please call us at 1-800-343-1113 for assistance.


The value of investments may go down as well as up and investors may not get back the full amount invested.

Diversification does not guarantee investment returns and does not eliminate the risk of loss.

Copyright 2023 JPMorgan Chase & Co. All rights reserved.